Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference

Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates

Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More

Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data

Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results

Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting

Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026

Upstream Bio to Participate in Upcoming March Investor Conferences

Upstream Bio's Selloff May Be 'Overdone,' But Analyst Highlights Asthma Drug's Competitive Edge Concerns

Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma

Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Consensus PT from Brokerages

Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Average Price Target from Brokerages

Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study

Upstream Bio to Participate in Upcoming December Investor Conferences

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio to Participate in Upcoming November Investor Conferences

Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug's Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress

Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

Upstream Bio (UPB) Q2 R&D Soars 169%

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Upstream Bio Appoints Stacy Price as Chief Technology Officer

Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Upstream Bio: Verekitug, A Longer-Acting Dupixent? - Key Data Is Imminent

Upstream Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Upstream Bio to Present at Upcoming March Investor Conferences

Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation

Upstream Bio Announces Addition to Russell 2000® Index

Discover the 3 Best-Performing Biotech IPO Stocks of 2024

Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Upstream Bio valued at $1.1 bln as shares jump in Nasdaq debut

Upstream Bio raises $255 mln in US IPO

Upstream Bio Announces Pricing of Upsized Initial Public Offering